Frontiers in Microbiology, 2021 QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya +8 more
doaj +1 more source
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics [PDF]
, 2021 Acute kidney injury represents a common complication in critically ill patients affected by septic shock and in many cases continuous renal replacement therapy (CRRT) may be required.
Gatti M., Pea F.
core +1 more source
2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
Open Forum Infectious Diseases, 2023 Abstract Background Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression ...
Castanheira, Mariana +3 more
openaire +1 more source
Infection and Drug Resistance, 2023 Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
doaj
Bicyclic Boronate β-Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens [PDF]
, 2021 The use of β-lactamase inhibitors in combination with β-lactam antibiotics is an emerging area in drug discovery. This strategy allows the restoration of the therapeutic efficacy of these antibiotics in clinical use against multiresistant bacteria. These
DeLano W. L. +5 more
core +1 more source
New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives [PDF]
, 2021 The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases ...
Pregnolato M., Taccani M., Terreni M.
core +1 more source
Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors
Pharmacy, 2019 Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover +2 more
doaj +1 more source
International Journal of Infectious Diseases, 2022 This case report describes a patient with post-neurosurgical infection and bacteremia caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
Seohyun Choi +4 more
doaj +1 more source
Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative <i>Klebsiella pneumoniae</i>. [PDF]
, 2020 Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam.
Avison, Matthew B +3 more
core +2 more sources
In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates. [PDF]
, 2023 A novel ß-lactam-β-lactamase inhibitor (BLBI), meropenem (MEM), combined with the boronate-based inhibitor vaborbactam (VAB), has recently been introduced for the treatment of infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing ...
Findlay, J., Nordmann, P., Poirel, L.
core +1 more source